Inflammatory bowel disease (IBD), as a global disease, has attracted much research
interest. Constant research has led to a better understanding of the disease condition and …

Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …

Background Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under
investigation for the treatment of inflammatory bowel disease. Methods We conducted a …

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has
multiple effective treatment options available and new therapeutic strategies are being …

Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …

Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

Inflammatory bowel diseases (IBDs), represented by Crohn disease and ulcerative colitis,
are associated with major morbidity in Western countries and with increasing incidence in …

Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …

Studies of bioactive lipids in general and sphingolipids in particular have intensified over the
past several years, revealing an unprecedented and unanticipated complexity of the …